Comparative study on dyspeptic symptom generation and gastroduodenal capsaicin/TRPV1 expression between Korea and Japan

Comparative study on dyspeptic symptom generation and gastroduodenal capsaicin/TRPV1 expression between Korea and Japan - Comparative study on dyspeptic symptom generation and gastroduodenal capsaicin/TRPV1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009673

Enrollment

200

Registered

2012-12-31

Start date

2012-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose symptoms fullfill Rome III criteria as shown below. One or more of the following: a. Bothersome postprandial fullness b. Early satiation c. Epigastric pain d. Epigastric burning AND No evidence of structural disease(including at upper endoscopy) that is likely to explain the symptoms * Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Exclusion criteria

Exclusion criteria: 1. Patients who have structural disease including erosive gastritis and GERD. 2. Patients who have history of upper GI operation 3. Patients whose causes of dyspepsia are obvious like taking much food, drink, NSAIDs, much stress, and so on. 4. Patients who have history of brain structual disease, schizophrenia, and depression. 5. Alcohol or drug dependent patients. 6. Patients who have severe disorder of endocrine system like hyperthyroidism. 7. Patients who have severe disorder of cardiovascular system, liver system, renal function, infection, and hematopoietic organ. 8. Patients who have allergic reaction for some drugs for gastrointestinal system. 9. Pregnancy or lactation woman. Patients who hope pregnancy during study. 10. Patients who took H. pylori eradication therapy within 6 months 11. Patients who are difficult to stop taking drugs like gastrointestinal drugs, anti-choline drugs, anti-depressant, and so on. 12. Suspitious for IBS 13. Any other patients which primary doctor judges them appropriate for this study.

Design outcomes

Primary

Measure	Time frame
PAGI-SYM	—

Secondary

Measure	Time frame
Dyspepsia-related score GERDQ HADS PAGI-QOL Life-style Food-life TRPV1 expression in duodenum TRPV1 polymorphism	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactHidekazu Suzuki

Department of Internal Medicine, Keio University School of Medicine Gastroenterology and hepatology

hsuzuki@a6.keio.jp03-5363-3914

Outcome results